WANECAM2 consortium reports positive results from Phase 2b study of novel treatment for children with malaria
New Orleans, 15 November 2024 – The West African Network for Clinical Trials of Antimalarial Drugs (WANECAM2) consortium is pleased to announce positive results from the Phase 2b KALUMI study of the novel, non-artemisinin drug ganaplacide combined with a new once-daily formulation of lumefantrine. KALUMI is a Phase 2 randomized, open-label, non-inferiority study evaluating the…